The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa

Publikation: Bidrag til tidsskriftLetterForskningfagfællebedømt

OriginalsprogEngelsk
TidsskriftBritish Journal of Dermatology
Vol/bind187
Udgave nummer2
Sider (fra-til)274-274
ISSN0007-0963
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
Conflicts of interest: H.C.R. has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from LEO Pharma. S.F.T. has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB.

ID: 313866645